JOINT TRAUMA SYSTEM CLINICAL PRACTICE GUIDELINE (JTS CPG)

Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) for Hemorrhagic Shock (CPG ID: 38)
Reviews the range of accepted management approaches to profound shock and post-traumatic cardiac arrest and establishes indications for considering REBOA as a hemorrhage control adjunct.

Contributors
Maj Jason Pasley, USAF, MC
Lt Col Jeremy Cannon, USAF, MC
CDR Jacob Glaser, MC, USN
CDR Travis Polk, MC, USN
MAJ Jonathan Morrison, RAMC
Maj Jason Brocker, USAF, MC
Lt Col Benjamin Mitchell, USAF, MC
Maj Justin Manley, USAF, MC
LTC Tyson Becker, MC, USA
Lt Col Joseph Dubose, USAF, MC
Col Todd Rasmussen, USAF, MC
Col Stacy Shackelford, USAF, MC
CAPT Zsolt Stockinger, MC, USN

First Publication Date: 16 Jun 2014
Publication Date: 06 Jul 2017
Supersedes CPG dated 16 Jun 2014

Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Services or DoD.

TABLE OF CONTENTS

Purpose .......................................................................................................................................................3
Background ....................................................................................................................................................3
RAO in Traumatic Arrest & Profound Shock .................................................................................................4
  Initial Management .......................................................................................................................................4
  Resuscitative Thoracotomy .........................................................................................................................5
  Trans-abdominal Aortic Occlusion ............................................................................................................5
  REBOA .......................................................................................................................................................5
Resources and Technique .............................................................................................................................6
REBOA Pitfalls .............................................................................................................................................6
Future Considerations .................................................................................................................................7
Performance Improvement (PI) Monitoring .................................................................................................7
  Intent (Expected Outcomes) .......................................................................................................................7
  Performance/Adherence Measures ............................................................................................................7
  Performance Improvement Data Capture and Reporting ...........................................................................8
Data Source ..................................................................................................................................................8
System Reporting & Frequency ..................................................................................................................8
Responsibilities ...........................................................................................................................................8
References ...................................................................................................................................................8
PURPOSE

This CPG reviews the range of accepted management approaches to profound shock and post-traumatic cardiac arrest and establishes indications to consider Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) as a hemorrhage control adjunct. The specific management approach—within the parameters of mission, resources, and tactical situation — will depend on the casualty’s physical location, mechanism and pattern of injury, and the experience level of the surgeon. The optimal management strategy is best determined by the clinician at the bedside.

BACKGROUND

- Hemorrhage is the leading cause of preventable death on the battlefield. Hemorrhage can be broadly categorized as compressible or non-compressible depending on its location. Non-Compressible Torso Hemorrhage (NCTH) arises from trauma to the torso vessels, pulmonary parenchyma, solid abdominal organs, or the bony pelvis. Because NCTH is occult and not amenable to control by direct pressure, it is particularly lethal.

- NCTH resulting in profound hypotension or shock does not improve with external cardiac compression. Instead Resuscitative Aortic Occlusion (RAO) may be required. This maneuver affords distal hemorrhage control while increasing cardiac afterload and central aortic pressure until direct hemostasis can be achieved. RAO has traditionally required a left thoracotomy or laparotomy for aortic exposure. Resuscitative thoracotomy has a high mortality rate, due largely to the nature of the injuries leading to arrest. Nonetheless, data from combat theaters indicate that there is a reasonable probability of long-term survival and recovery following RAO in appropriately selected casualties as described in the JTS Emergent Resuscitative Thoracotomy CPG.

- ERT also allows management of thoracic injuries and manual cardiac compression. ERT is the procedure of choice for patients with significant thoracic or cardiac injury and may improve cardiac index, coronary and cerebral perfusion pressure compared to closed chest compression.

- REBOA is an alternative approach to RAO in patients at risk of imminent cardiovascular collapse performed through a femoral artery approach without the need for thoracotomy. This approach is best when the site of hemorrhage is below the diaphragm and no open thoracic intervention is needed.

- Most of the current clinical literature on REBOA have been equivocal, with some studies demonstrating survival benefit, while others showing it may actually worsen mortality. Thus far, there has only been one prospective clinical study on REBOA, which showed no difference in survival when compared to open aortic occlusion.

- Balloon aortic occlusion was first described as a resuscitative intervention by Hughes in 1954 in two moribund combat casualties. Since this early publication, REBOA has been further explored as an adjunct to resuscitation.

- In recent years, renewed interest in balloon aortic occlusion for resuscitation prompted detailed analysis of REBOA in the animal laboratory. Animal experiments demonstrated the potential merits of REBOA with occlusion times of up to 90 minutes. Additional clinical analysis has supported usage.

- Significant improvements in endovascular equipment and growing experience in endovascular techniques have advanced the use of REBOA. Specific applications now include proximal aortic occlusion for management of ruptured abdominal aortic aneurysm, elective oncologic resections, pelvic hemorrhage from gynecologic pathology, and traumatic NCTH. Thus, REBOA appears suited to
serve as a temporary, minimally invasive bridge to definitive surgical or endovascular hemorrhage control.

- There is one published case series of four patients in whom REBOA was successfully utilized in a military austere location. Since balloon aortic occlusion provides a less invasive and expedient means to control life threatening hemorrhage in appropriately selected casualties, this intervention could be considered as an option to temporarily control life-threatening hemorrhage in the setting of abdominal, pelvic, or junctional lower extremity injury until definitive surgical hemostasis can be achieved. The implementation of this technique must be determined at each site based on training, experience, local resources, and evacuation timelines.

RAO IN TRAUMATIC ARREST & PROFOUND SHOCK

Given the lack of large-scale human studies demonstrating the effectiveness of REBOA over other RAO techniques, the precise indications for REBOA placement are open to debate. However, suggested indications are summarized below. These indications mirror the indications for resuscitative thoracotomy with the exception that shock or arrest secondary to penetrating chest trauma is a relative contraindication to REBOA.

INITIAL MANAGEMENT

Initial management priorities for patients with traumatic arrest or impending arrest include early control of hemorrhage and hemostatic resuscitation as described in the JTS Damage Control Resuscitation CPG. Closed chest cardiac massage has little benefit if the intravascular space is empty. Thus, the initial focus in patients presenting in profound hemorrhagic shock, to include loss of pulses, must be to rapidly determine the following:

- Mechanism and pattern of injury
- Presence of a pulse
- Duration of cardiac arrest
- Presence or absence of an organized, narrow complex cardiac rhythm and/or organized cardiac activity by ultrasound.
- Resources available
- Number of concurrent casualties

Consideration of these factors can assist in determining the best resuscitative strategy, or making the decision to terminate efforts in a moribund patient.

Patients exsanguinating from abdominal, pelvic, or junctional lower extremity bleeding may be candidates for REBOA. Such patients are identified by penetrating mechanism of injury to abdomen or pelvis, blast or blunt mechanism with positive FAST or suspected pelvic fracture, or massive proximal lower extremity trauma with signs of impending cardiovascular collapse.

Exsanguinating hemorrhage in the chest must be evaluated prior to placing REBOA—this can be done with chest tube placement, chest x-ray, or thoracic ultrasound. In cases of chest hemorrhage, occlusion of the aorta may increase thoracic bleeding and should be done with awareness of the physiologic consequences.

A decision algorithm for RAO is found in Appendix A. If RAO is performed, volume resuscitation with closed chest cardiac massage can continue while the surgeon initiates the procedure. If RAO is not performed, resuscitative efforts should cease unless there is a compelling reason to consider a non-traumatic arrest.
Early recognition of hemorrhagic shock will facilitate identification of patients who may benefit from REBOA. Although unproven, application of REBOA prior to arrest may lead to improved outcomes.\(^{37}\) (Appendix B)

In clinical situations where REBOA placement is being considered, pre-emptive placement of an arterial line in the common femoral artery in hemodynamically unstable trauma patients may facilitate REBOA placement in the event of patient deterioration since the arterial line can be quickly re-wired to an introducer for REBOA placement.

Ideally, REBOA should be performed prior to cardiac arrest as survival from cardiac arrest remains low for patients treated with either REBOA or resuscitative thoracotomy. If SBP is < 90 with only transient or no response to initial resuscitation to include infusion of blood products, REBOA may be considered if the environment, equipment, supplies, and team training support the procedure.

The decision to perform REBOA on such patients at high risk for hemorrhagic death will depend on the specific injury pattern, individual provider experience, and local resources.

**RESUSCITATIVE THORACOTOMY**

Based on current trauma guidelines, the gold standard for aortic occlusion in traumatic arrest is a left anterolateral thoracotomy (See JTS Emergent Resuscitative Thoracotomy CPG\(^{16}\)).

**TRANS-ABDOMINAL AORTIC OCCLUSION**

The aorta can also be occluded trans-abdominally at any point along its length. It can be occluded with either application of a clamp or compression with a retractor or manually. Balloon occlusion can be considered (below) as this can decrease instruments in the upper abdomen, depending on where the focus of bleeding is located. In obese patients with a large volume of hemoperitoneum or other intra-abdominal pathology, a trans-thoracic approach or a balloon approach to the aorta may be preferable. As with all other forms of RAO, restoration of aortic perfusion should be carefully coordinated with the rest of the team to minimize the effects of reperfusion and blood volume shifts.

**REBOA**

REBOA is an alternative approach to resuscitative thoracotomy for aortic occlusion in some cases of traumatic arrest. Furthermore, REBOA can be performed preemptively in patients with high-risk injury patterns and unstable physiologic parameters as described above. In this way, REBOA can be proactive rather than reactive in appropriate patients. The indications for REBOA are summarized in Appendix A for traumatic arrest and Appendix B in cases of profound shock. A schematic of the aortic anatomy is presented in Appendix C.\(^{26}\) If proximal aortic occlusion is required, this is termed Zone I whereas distal aortic occlusion is termed Zone III.

Although clinical data are currently being collected through an AAST multi-center database,\(^{22}\) there is currently a paucity of evidence to guide the specific length of time that the aorta may be safely occluded, limiting its application to locations where a surgical team is immediately available. Current clinical experience suggests that Zone I REBOA may be placed for 30-60 minutes, and Zone III REBOA may potentially stay up for a longer period of time if necessary.
RESOURCES AND TECHNIQUE

REBOA can be considered in six sequential steps:

1. Arterial access and positioning of sheath
2. Selection and positioning of the balloon
3. Inflation of the balloon
4. Operative/procedural control of bleeding
5. Deflation of the balloon
6. Sheath removal

The essential equipment for REBOA is provided in Appendix D while the appropriate technical steps and considerations are summarized in Appendix E.

REBOA PITFALLS

- Making the decision to perform REBOA too late. Mortality is high after loss of pulses has occurred, as it is with ERT.22
- Difficulty locating the common femoral artery in the groin. The clinician must be very familiar with open, percutaneous, and ultrasound guided femoral access techniques.
- Insertion of the REBOA too low, below the femoral artery bifurcation. The catheter should be placed in the common femoral artery, just below the inguinal ligament.
- Unrecognized proximal femoral or iliac artery transection preventing endovascular access on the side of the injury. This may occur with penetrating pelvic trauma or severe pelvic fracture—check bilateral femoral pulses and access the side with a stronger pulse if there is a difference. Do not hesitate to switch to the opposite groin or convert to thoracotomy.
- Failure to address chest pathology. Always evaluate the chest by X-ray, ultrasound, or bilateral chest tube placement to identify and treat significant hemothorax or pneumothorax. Convert to thoracotomy to address massive hemothorax.
- Catheter or guidewire does not pass freely. This could indicate injury to the vessel. Do not inflate balloon. Consider accessing the opposite groin or convert to thoracotomy.
- Over-inflating the balloon. The ER REBOA balloon capacity is 24 ml. Over-inflation will rupture the balloon. Zone I typically requires approximately 8 ml, while Zone III requires approximately 3 ml to achieve occlusion.
- Leaving the balloon inflated too long. Only 30-60 minutes of Zone I occlusion are advised, and the shorter the better. Achieve rapid control of bleeding sites with temporizing measures such as clamping to allow the earliest reperfusion; most suturing, ligating, solid organ removal, and vascular shunting may be done after balloon deflation.
• Failure to work with a heightened level of urgency once REBOA is placed. Some patients may regain “stability,” however balloon occlusion is just like a cross clamp, with the same complications of visceral and spinal ischemia. Every effort should be made to take this down as soon as possible to limit ischemia/reperfusion.

• Failure to adequately secure the REBOA catheter after balloon inflation resulting in migration of the balloon due to proximal aortic distension with restoration of blood pressure.

• Deflating the balloon too quickly before adequate volume resuscitation. Ensure that anesthesia is ready with appropriate volume resuscitation prior to balloon deflation.

• Removal of the arterial sheath too soon. If the patient remains coagulopathic, may have ongoing bleeding in the abdomen or pelvis, or is being transported within theater to a higher level of care, consider leaving the sheath in position.

• Injury to the arterial access point. After removal of the sheath, monitor the instrumented leg closely for re-bleeding and thrombus/intimal injury. Decreased lower extremity perfusion may require further angiography, thrombectomy, or direct arterial repair.  

• Committing multiple resources to a futile resuscitation. Anticipate massive transfusion, personnel required, surgical supplies, diversion of resources from more salvageable casualties, etc.

FUTURE CONSIDERATIONS

A retrospective capability gap analysis of the UK Joint Theatre Trauma Registry suggested that as many as one in five severely injured casualties may have wounds that maybe amenable to treatment with REBOA. The development of the 7 Fr ER REBOA catheter facilitates the ease of placement of the device and may lead to more widespread use of this approach in the austere environment. External landmarks are undergoing validation for REBOA insertion and surgeon/emergency medicine training in REBOA is ongoing at multiple centers. All of these advances should facilitate appropriate clinical evaluation of REBOA to determine the optimal use of this resuscitation adjunct.

PERFORMANCE IMPROVEMENT (PI) MONITORING

INTENT (EXPECTED OUTCOMES)

• If performed, REBOA was performed for hemorrhagic shock associated with uncontrolled abdominal, pelvic, or junctional lower extremity bleeding.

• The chest was evaluated at the time of REBOA placement (ultrasound, chest-X-ray, or chest tube) for contraindications to REBOA placement.

• Abdominal FAST exam was documented at the time of REBOA placement.

PERFORMANCE/ADHERENCE MEASURES

• If performed, REBOA was performed for hemorrhagic shock associated with uncontrolled abdominal, pelvic, or junctional lower extremity bleeding.
The chest was evaluated at the time of REBOA placement (ultrasound, chest-X-ray, or chest tube) for contraindications to REBOA placement.

Abdominal FAST exam was documented at the time of REBOA placement.

REBOA was performed only in patients with signs of hemorrhagic shock.

All applications of REBOA are identified to JTS to ensure appropriate capture of data in the DoDTR.

All REBOA-related complications are documented in the medical record.

PERFORMANCE IMPROVEMENT DATA CAPTURE AND REPORTING

- Number of REBOA interventions, performance, and adherence measures will be reported quarterly by JTS PI Branch Chief to the JTS Director.
- JTS will identify REBOA patients in the trauma registry and facilitate capture of complete medical records.

DATA SOURCE

- Patient Record
- Department of Defense Trauma Registry (DoDTR)

SYSTEM REPORTING & FREQUENCY

The above constitutes the minimum criteria for PI monitoring of this CPG. System reporting will be performed annually; additional PI monitoring and system reporting may be performed as needed.

The system review and data analysis will be performed by the JTS Director, JTS Program Manager, and the JTS Performance Improvement Branch.

RESPONSIBILITIES

It is the responsibility of the Chief, JTS PI Branch, to ensure system-level compliance with this CPG. It is the trauma team leader’s responsibility to ensure familiarity, appropriate compliance and PI monitoring at the local level with this CPG.

REFERENCES


Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) for Hemorrhagic Shock

APPENDIX A: TRAUMATIC ARREST ALGORITHM FOR REBOA


Zone I REBOA: placement of aortic balloon in the thoracic aorta (insert catheter to 46 cm or measure the balloon to mid sternum/P-tip to sternal notch)

Zone III REBOA: placement of aortic balloon directly above the aortic bifurcation (insert catheter to 27 cm or measure the balloon to the umbilicus).
APPENDIX B: ALGORITHM FOR THE USE OF REBOA FOR PROFOUND SHOCK

SBP<90 with Transient or No Response to initial ATLS Resuscitation

- **Blunt Trauma**
  - **Severe Chest Injury?***
    - Yes: No REBOA
    - No
      - Abdominal FAST Positive?
        - Yes: Consider Zone I REBOA
          - Emergent Laparotomy
        - No
          - Pelvic Fx?
            - Yes: Consider Zone III REBOA
            - No
              - Penetrating
                - Neck: REBOA not indicated
                  - Operating room
                - Chest: REBOA not indicated
                  - Consider thoracotomy
                - A/P/J: Consider Zone I REBOA
                - Extremity: Tourniquet, Resuscitate

REBOA: Resuscitative Endovascular Balloon Occlusion of the Aorta; ATLS: Advanced Trauma Life Support; ROSC: Return of Spontaneous Circulation; CXR: Chest X-Ray; EFAST: Extended Focused Assessment with Sonography for Trauma; FAST: Focused Assessment with Sonography for Trauma; A/P/J: Abdomen/Pelvis/Junctional Lower Extremity.

Zone I REBOA: placement of aortic balloon in the thoracic aorta (insert catheter to 46 cm or measure the balloon to mid sternum/P-tip to sternal notch)

Zone III REBOA: placement of aortic balloon directly above the aortic bifurcation (insert catheter to 27 cm or measure to the level of the umbilicus).
APPENDIX C: AORTIC ZONES¹⁹
APPENDIX D: EQUIPMENT AND SUPPLIES FOR REBOA

- 5 Fr micropuncture set or 18 Ga arterial line set (e.g., Cook Medical G43870, NSN 6515016591707; or Vascular Solutions, Inc 7208V; or Arrow Femoral Arterial Line UM-04018)
- 7 Fr arterial sheath (e.g., ER REBOA Catheter Introducer kit, Prytime Medical KT1835C; or Cordis Avanti 402-607x, NSN 6515016594864)
- ER REBOA catheter (Prytime Medical, NSN 6515016580745)
- Central line securement device
- Suture
- Ultrasound (linear probe for vascular access)
- Ultrasound probe cover
- Scalpel (#11 or #15)
- Surgical set for open femoral artery exposure
- Silk ties
- Full body drapes
- 10 ml Luer lock syringe x2
- 5 ml Luer lock syringe x1
- 3-way stopcock
- Injectable saline (100 mL)
- Intravenous contrast (mix 10 mL in 20 mL injectable saline for balloon)
- Standard A-line setup
APPENDIX E: REBOA STEPS USING THE 7 FRENCH ER-REBOA

The procedure may reviewed online using the following links:

Part 1: https://www.youtube.com/watch?v=-U7MkU3eA7E

Part 2: https://www.youtube.com/watch?v=DZ5LCEt7PBk

STEP 1: ARTERIAL ACCESS AND POSITIONING OF THE SHEATH

Establishing Arterial Access:

Access to the arterial circulation for REBOA for trauma should be obtained through the common femoral artery using one of three techniques: percutaneous, open exposure (e.g., cut down), or exchange over a guide wire from an existing common femoral arterial line. Percutaneous access can be obtained via landmark identification or ultrasound. Using landmarks, the location of the inguinal ligament is identified between the Anterior Superior Iliac Spine (ASIS) and pubic symphysis. The common femoral artery is then accessed 2 cm below the inguinal ligament. Alternatively, ultrasound is used to identify the common femoral artery above the branch of the profunda and the needle visualized passing into the common femoral artery (linear array transducer preferred). Ultrasound or direct surgical identification of the femoral artery is especially important in the hypotensive patient with no palpable pulse. Once identified, the artery should be entered at a 45-degree angle with the needle, using either a 5 Fr micropuncture kit or 18 gauge femoral arterial line kit. After the wire has been passed into the artery, the needle is removed and a small incision made at the interface of the wire and skin and the catheter is passed over the wire.

Selection and Positioning of Initial Sheath:

If REBOA is indicated, the arterial access catheter must be upsized to a 7 Fr sheath if an 18 gauge or 5 Fr arterial catheter was placed initially. This maneuver is accomplished by placing a 0.035 guide wire greater than twice the length of the existing arterial catheter through its inner lumen allowing the catheter to be removed over the wire while maintaining arterial access. After a larger opening is created at the wire/skin interface, the 7 Fr working sheath with its internal dilator in position can be inserted over the wire. When urgently needed, a 7 Fr sheath may be placed as the initial step by placing the 7F sheath over the 0.035 guide wire.

It is important that any time a sheath is passed over a wire into the arterial system, the sheath’s internal dilator is firmly held in place to allow a smooth reverse taper from the wire to the diameter of the sheath to avoid arterial intimal injury. Once the dilator and sheath have been advanced over the wire through the skin into the artery, the dilator and wire are removed, leaving the sheath in place. To avoid bleeding from the side port of the sheath after the dilator is removed, it is important that the operator assure that the stopcock is in the “off” position to the patient.

STEP 2: SELECTION AND POSITIONING OF THE BALLOON

Selection of a Balloon:

The balloon which is best suited for austere environments is the ER REBOA (Prytime Medical) which is wire-free and smaller caliber than previously used balloons, allowing fewer steps for insertion and a smaller introducer sheath (7 Fr). It also has arterial pressure monitoring capability.

Alternative balloons should only be used by personnel with experience in the use of the specific catheter. Examples of compliant balloons suitable for aortic occlusion include: (1) Coda balloon (Cook Medical): 32 mm to
40 mm, 14 Fr; (2) Reliant balloon (Medtronic): 10 mm to 46 mm, 12 Fr; and (3) Berenstein balloon (Boston Scientific): 11.5 mm, 6 Fr.

**Balloon Preparation:**

The ER REBOA balloon should be prepared by attaching a 25 ml syringe to the balloon port and ensuring that all air is evacuated from the balloon. The stop-cock can then be turned to the off position toward the balloon to ensure negative pressure within the balloon and allow the balloon to pass easily into the peel-away sheath.

If using the pressure monitoring capabilities, the pressure sensor and tubing should be attached to the catheter’s arterial stopcock and flushed with saline using standard arterial line setup and transducer connected to a monitor. Once the catheter is inserted, care must be taken to prevent inadvertent emboli (air, thrombus, etc.). This can be accomplished by always aspirating the catheter prior to flushing while the catheter is in place.

**Balloon Positioning:**

Aortic zones are designated Zone I, II, and III spanning from proximal to distal (Appendix C). Zone I is the descending thoracic aorta between the origin of the left subclavian to the celiac artery. Zone II is the paravisceral aorta between the celiac artery and the lowest renal artery and Zone III is the infrarenal aorta between the lowest renal artery and the aortic bifurcation. In most instances of shock and impending cardiovascular collapse, the goal is to position the balloon in Zone I, similar to an open thoracic aorta cross-clamp. Inflation of a balloon in Aortic Zone III is used for control of pelvic or junctional femoral hemorrhage.

For Zone I occlusion, the catheter should be inserted 46 cm (or measured with the balloon from the mid-sternal/P-tip from the sternal notch to the femoral access catheter). For Zone III occlusion, the P-tip should be inserted 27 cm (or measured from the umbilicus to the femoral access catheter). Distances are noted on the catheter shaft. The peel away sheath is advanced over the P-tip and balloon to protect these as they enter the 7F sheath. The peel away sheath is advanced into the end of the 7F sheath approximately 5mm or until it hits a “stop.” The REBOA catheter is then advanced 10-20 cm into the sheath. The peel away sheath can then be slid back onto the catheter hub or removed, if full advancement is necessary. The catheter should be advanced to the predetermined depth. Plain film x-ray, ultrasound, or fluoroscopy can confirm correct positioning of the catheter and adjustments can be made if necessary, prior to inflation. There are two radio-opaque markers on the catheter to designate the location of the balloon.

**STEP 3: INFLATION OF THE BALLOON AND SECURING OF THE APPARATUS**

**Inflation of the Balloon:**

A 10 ml syringe is filled with a 1:1 solution of sterile saline and iodinated contrast. The balloon should be inflated until the blood pressure is augmented and contralateral femoral pulse is stopped, approximately 8 ml for Zone I or 3 ml for Zone III. Do not over-inflate the balloon—balloon capacity is 24 ml—over-inflation will rupture the balloon or the blood vessel. If contrast or X-ray is not available, only sterile saline is used, however the use of contrast allows visualization of balloon inflation on X-ray and dilution allows rapid inflation and deflation times by reducing the viscosity of full-strength contrast. Balloon inflation should be guided by fluoroscopy, hemodynamic response, and/or loss of the contralateral pulse. When fluoroscopy is available, inflate the balloon until the outer edges of the balloon change from convex to parallel as the balloon takes on the contour of the aortic wall. When inflation appears adequate to gain aortic wall apposition and/or central blood pressure is augmented, the three-way stopcock on the shaft of the balloon should be turned off toward the balloon to maintain inflation and occlusion while other maneuvers are undertaken. If image guidance was not used for inflation, a confirmatory X-ray or ultrasound is recommended for radiographic confirmation of location. If no imaging is available in the austere environment, definitive confirmation of the balloon positioning should be accomplished directly with “hands-on” at the time of laparotomy. If the balloon is found to be mal-positioned (e.g., Zone II) the balloon should be deflated and catheter positioned to Zone I or III and the balloon re-inflated.
Care should be made not to over-inflate the balloon as this may rupture the balloon and may damage or rupture the vessel.

Securing the Inflated Balloon and Sheath:

As the central aortic pressure improves, the catheter may be pushed caudally. To prevent catheter migration, a central line attachment device is sutured to the skin as close as possible to the sheath. For added monitoring and security, assign an assistant the task of holding the apparatus until balloon deflation is desired.

The assistant should monitor and communicate the “big three” factors imperative to maintenance of successful REBOA: mean arterial pressure, maintenance of position, and maintenance of occlusion (balloon inflation).

STEP 4: OPERATIVE/PROCEDURAL CONTROL OF BLEEDING

Control of bleeding below the diaphragm must occur very quickly when a Zone I REBOA is in place, with a goal to keep the total aortic occlusion time as short as possible, preferably less than 30 minutes and no more than 60 minutes. It is therefore important to start with temporizing maneuvers to control bleeding such as clamping of the splenic or renal hilum, Pringle maneuver, clamping of any injured blood vessel, packing, or obtaining proximal and distal control of an injured blood vessel. At times, definitive control of bleeding such as solid organ removal, ligation of clamped vessels, or vascular shunt placement, may be deferred until after the REBOA has been deflated.

Interventional radiology embolization may be considered when available, particularly with pelvic fractures after intra-abdominal hemorrhage has been ruled out or controlled and the REBOA has been positioned in Zone III.

STEP 5: DEFLATION OF THE BALLOON

Once specific vascular control or definitive hemorrhage control has been obtained, balloon deflation should be performed. Communication with the assistant holding the apparatus and the anesthesia team is critical before consideration of balloon deflation. Once a decision to attempt deflation is made, care must be taken to turn the three-way stopcock and deflate the balloon slowly as this step can be anticipated to result in a significant decrease in afterload and hypotension. Generally speaking, the main operator should be the person to deflate the balloon while the identified assistant continues to hold the balloon and sheath in the desired location. After deflation of the balloon, the team should anticipate hemodynamic changes related to reperfusion, washout of metabolic byproducts, and acidosis. As such, intermittent balloon inflation and deflation may be necessary with ongoing resuscitation until some hemodynamic stability is restored.

STEP 6: REMOVAL OF THE BALLOON AND SHEATH

After REBOA is no longer required, the deflated balloon may be removed from the 7 Fr sheath. The side port of this sheath can be used for arterial pressure monitoring. If the sheath is no longer necessary and coagulation has normalized, then the sheath can be removed. Ideally, the sheath should then be flushed with 100 mL of heparinized saline (1,000 units of heparin in 1 L of saline) as some thrombus may have formed during the process. If placed percutaneously, the sheath may be removed and direct pressure held at the arterial site, above the skin puncture site. Full occlusive direct pressure is held for 10 minutes, with gradual decrease in pressure every 5 minutes for 30 minutes total.

If the introducer sheath was placed by open arterial cutdown, then open surgical repair of the arterial access site is necessary. The femoral artery proximal and distal to the sheath entry site should be exposed to allow control. Proximally, this may require dissection for 2 cm to 3 cm underneath the inguinal ligament as an assistant uses a narrow handheld retractor (e.g., short Wylie renal vein retractor) to lift the inguinal ligament off of the femoral sheath. During this maneuver, the surgeon must be mindful of the circumflex iliac veins which course over the
top of the distal external iliac and proximal common femoral artery. Exposure distal to the sheath entry site often requires identification and control of both the superficial and profunda femoris arteries. Once proximal and distal exposure and control with vessel loops or vascular clamps have been accomplished, the sheath may be removed. Consideration should be made for passage of embolectomy catheters distally to remove any potential clot and assure back bleeding. The resulting arteriotomy, especially the intima, should be closely examined and tailored with Potts scissors if necessary to allow primary transverse closure. Closure of the arteriotomy should be performed transversely using 5-0 or 6-0 permanent monofilament suture in either an interrupted or running fashion with care to capture all layers of the arterial wall with passage of the needle. Before closing the last suture, forward bleeding and back bleeding of the arterial segments should be allowed followed by flushing of the surface with heparinized saline. Restoration of flow through the arterial segment should be confirmed using manual palpation for pulses distally and use of continuous wave Doppler of both the artery and more distal extremity. If there is any question of flow, it is recommended to perform an angiogram and appropriate intervention if any abnormalities are noted. Closure of the soft tissues above the femoral artery is accomplished in layers using absorbable suture in the soft tissues.
APPENDIX F: ER-REBOA PROCEDURE CHECKLIST

1. Resuscitate per ATLS
2. “Clear” chest (CXR/EFAST/Bilateral chest tubes)
3. FAST abdomen
4. Pelvic X-ray if blunt trauma
5. Check bilateral femoral pulses
6. Establish arterial access with 7 Fr Sheath
7. Measure balloon distance
8. Evacuate the balloon
9. Flush the arterial line
10. Insert the catheter
11. Inflate the balloon
12. Secure the catheter
13. Control major bleeding
14. Resuscitate and deflate the balloon
15. Complete damage control surgery
16. Remove sheath when coagulopathy corrected
17. Check distal pulses after sheath removal
APPENDIX G: ADDITIONAL INFORMATION REGARDING OFF-LABEL USES IN CPGS

PURPOSE

The purpose of this Appendix is to ensure an understanding of DoD policy and practice regarding inclusion in CPGs of “off-label” uses of U.S. Food and Drug Administration (FDA)–approved products. This applies to off-label uses with patients who are armed forces members.

BACKGROUND

Unapproved (i.e., “off-label”) uses of FDA-approved products are extremely common in American medicine and are usually not subject to any special regulations. However, under Federal law, in some circumstances, unapproved uses of approved drugs are subject to FDA regulations governing “investigational new drugs.” These circumstances include such uses as part of clinical trials, and in the military context, command required, unapproved uses. Some command requested unapproved uses may also be subject to special regulations.

ADDITIONAL INFORMATION REGARDING OFF-LABEL USES IN CPGS

The inclusion in CPGs of off-label uses is not a clinical trial, nor is it a command request or requirement. Further, it does not imply that the Military Health System requires that use by DoD health care practitioners or considers it to be the “standard of care.” Rather, the inclusion in CPGs of off-label uses is to inform the clinical judgment of the responsible health care practitioner by providing information regarding potential risks and benefits of treatment alternatives. The decision is for the clinical judgment of the responsible health care practitioner within the practitioner-patient relationship.

ADDITIONAL PROCEDURES

1.0 Balanced Discussion

Consistent with this purpose, CPG discussions of off-label uses specifically state that they are uses not approved by the FDA. Further, such discussions are balanced in the presentation of appropriate clinical study data, including any such data that suggest caution in the use of the product and specifically including any FDA-issued warnings.

2.0 Quality Assurance Monitoring

With respect to such off-label uses, DoD procedure is to maintain a regular system of quality assurance monitoring of outcomes and known potential adverse events. For this reason, the importance of accurate clinical records is underscored.

3.0 Information to Patients

Good clinical practice includes the provision of appropriate information to patients. Each CPG discussing an unusual off-label use will address the issue of information to patients. When practicable, consideration will be given to including in an appendix an appropriate information sheet for distribution to patients, whether before or after use of the product. Information to patients should address in plain language: a) that the use is not approved by the FDA; b) the reasons why a DoD health care practitioner would decide to use the product for this purpose; and c) the potential risks associated with such use.